Apimeds Pharmaceuticals US, Inc.
$1.67
$0.07 (+4.37%)
$1.60Day Range$1.92
Key Statistics
Market Cap
$2.52M
Shares Outstanding
1.5M
Primary Exchange
XASE
Currency
USD
Type
CS
IPO Date
May 9, 2025
Round Lot
100
Locale
US
Trading Data
Day Open
$1.73
Day High
$1.92
Day Low
$1.60
Volume
84.0K
VWAP
$1.72
Prev Close
$1.60
Transactions
--
Acc. Volume
--
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
PHARMACEUTICAL PREPARATIONSSIC 28347 employees100 MATAWAN RD, MATAWAN, NJ, 07747848-201-5010IPO May 9, 2025US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001894525
- Composite FIGI
- BBG01Q0T3D78
- Share Class FIGI
- BBG01Q0T3FL7
- Ticker Root
- APUS
- SIC Code
- 2834
About Apimeds Pharmaceuticals US, Inc. (APUS) Stock
Apimeds Pharmaceuticals US, Inc. (APUS) closed the 2026-09-17 session at $1.67, up 4.37% versus the previous close (+0.07). The stock opened at $1.73 and traded between $1.60 and $1.92 during that session. Session trading volume was 84K shares. The volume-weighted average price (VWAP) is $1.72.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
Apimeds Pharmaceuticals US, Inc. has a market capitalization of $2.5 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. APUS is listed on the XASE exchange. The company employs approximately 7 people. Apimeds Pharmaceuticals US, Inc. is headquartered in MATAWAN, NJ. The recorded listing date is 2025-05-09.
On this page you can find market APUS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.